|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS5 |
Gene summary for MRPS5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS5 | Gene ID | 64969 |
| Gene name | mitochondrial ribosomal protein S5 | |
| Gene Alias | MRP-S5 | |
| Cytomap | 2q11.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P82675 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64969 | MRPS5 | LZE4T | Human | Esophagus | ESCC | 3.28e-17 | 6.90e-01 | 0.0811 |
| 64969 | MRPS5 | LZE5T | Human | Esophagus | ESCC | 8.54e-03 | 5.86e-01 | 0.0514 |
| 64969 | MRPS5 | LZE7T | Human | Esophagus | ESCC | 7.27e-07 | 4.20e-01 | 0.0667 |
| 64969 | MRPS5 | LZE8T | Human | Esophagus | ESCC | 1.87e-08 | 2.99e-01 | 0.067 |
| 64969 | MRPS5 | LZE20T | Human | Esophagus | ESCC | 4.36e-05 | 1.40e-01 | 0.0662 |
| 64969 | MRPS5 | LZE21D1 | Human | Esophagus | HGIN | 1.70e-04 | 4.54e-01 | 0.0632 |
| 64969 | MRPS5 | LZE22D1 | Human | Esophagus | HGIN | 7.52e-07 | 2.38e-01 | 0.0595 |
| 64969 | MRPS5 | LZE22T | Human | Esophagus | ESCC | 6.79e-09 | 6.84e-01 | 0.068 |
| 64969 | MRPS5 | LZE24T | Human | Esophagus | ESCC | 8.51e-16 | 4.21e-01 | 0.0596 |
| 64969 | MRPS5 | LZE21T | Human | Esophagus | ESCC | 8.45e-06 | 6.04e-01 | 0.0655 |
| 64969 | MRPS5 | P1T-E | Human | Esophagus | ESCC | 3.58e-09 | 5.91e-01 | 0.0875 |
| 64969 | MRPS5 | P2T-E | Human | Esophagus | ESCC | 1.47e-41 | 7.95e-01 | 0.1177 |
| 64969 | MRPS5 | P4T-E | Human | Esophagus | ESCC | 1.77e-35 | 9.09e-01 | 0.1323 |
| 64969 | MRPS5 | P5T-E | Human | Esophagus | ESCC | 8.06e-32 | 5.89e-01 | 0.1327 |
| 64969 | MRPS5 | P8T-E | Human | Esophagus | ESCC | 1.93e-29 | 5.29e-01 | 0.0889 |
| 64969 | MRPS5 | P9T-E | Human | Esophagus | ESCC | 3.28e-25 | 5.07e-01 | 0.1131 |
| 64969 | MRPS5 | P10T-E | Human | Esophagus | ESCC | 3.85e-61 | 1.11e+00 | 0.116 |
| 64969 | MRPS5 | P11T-E | Human | Esophagus | ESCC | 2.38e-20 | 8.95e-01 | 0.1426 |
| 64969 | MRPS5 | P12T-E | Human | Esophagus | ESCC | 2.52e-48 | 9.55e-01 | 0.1122 |
| 64969 | MRPS5 | P15T-E | Human | Esophagus | ESCC | 3.26e-42 | 9.57e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301039 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010115 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS5 | deletion | Frame_Shift_Del | c.336delA | p.Gly113GlufsTer14 | p.G113Efs*14 | P82675 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| MRPS5 | SNV | Missense_Mutation | novel | c.635N>C | p.Gly212Ala | p.G212A | P82675 | protein_coding | deleterious(0) | possibly_damaging(0.717) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| MRPS5 | SNV | Missense_Mutation | novel | c.289G>A | p.Glu97Lys | p.E97K | P82675 | protein_coding | deleterious(0.04) | benign(0.052) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| MRPS5 | deletion | Frame_Shift_Del | c.336delN | p.Gly113GlufsTer14 | p.G113Efs*14 | P82675 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |||
| MRPS5 | SNV | Missense_Mutation | rs142603460 | c.406N>T | p.Arg136Cys | p.R136C | P82675 | protein_coding | deleterious(0) | possibly_damaging(0.614) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRPS5 | SNV | Missense_Mutation | c.372N>T | p.Lys124Asn | p.K124N | P82675 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-CM-6165-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS5 | SNV | Missense_Mutation | c.899G>T | p.Arg300Met | p.R300M | P82675 | protein_coding | deleterious(0.01) | possibly_damaging(0.895) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| MRPS5 | SNV | Missense_Mutation | c.902C>A | p.Thr301Lys | p.T301K | P82675 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AG-3728-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR | |
| MRPS5 | SNV | Missense_Mutation | novel | c.548N>G | p.Lys183Arg | p.K183R | P82675 | protein_coding | tolerated(1) | benign(0) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
| MRPS5 | SNV | Missense_Mutation | rs762570404 | c.1051N>T | p.Arg351Cys | p.R351C | P82675 | protein_coding | tolerated(0.18) | possibly_damaging(0.717) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |